ED
GILD icon

Exane Derivatives’s Gilead Sciences GILD Stock Holding History

Exane Derivatives’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$837K Sell
13,537
-4,847
-26% -$300K 0.48% 51
2022
Q1 		$1.09M Buy
18,384
+3,636
+25% +$232K 0.31% 81
2021
Q4 		$1.07M Buy
14,748
+586
+4% +$40.4K 0.26% 82
2021
Q3 		$989K Buy
14,162
+9,521
+205% +$669K 0.24% 92
2021
Q2 		$316K Sell
4,641
-1,201
-21% -$80.2K 0.07% 274
2021
Q1 		$378K Buy
5,842
+493
+9% +$31.8K 0.11% 187
2020
Q4 		$312K Sell
5,349
-15,592
-74% -$941K 0.09% 240
2020
Q3 		$1.32M Sell
20,941
-11,900
-36% -$825K 0.38% 57
2020
Q2 		$2.53M Buy
32,841
+26,103
+387% +$2M 0.68% 37
2020
Q1 		$504K Hold
6,738
– – 0.14% 125
2019
Q4 		$432K Sell
6,738
-52,721
-89% -$3.43M 0.08% 187
2019
Q3 		$3.77M Sell
59,459
-557
-0.9% -$36.4K 0.68% 32
2019
Q2 		$4.05M Sell
60,016
-6,136
-9% -$404K 0.71% 30
2019
Q1 		$4.3M Buy
+66,152
New +$4.4M 0.85% 27
2018
Q2 		– Sell
-4,527
Closed -$338K – 690
2018
Q1 		$338K Sell
4,527
-9,856
-69% -$783K 0.07% 184
2017
Q4 		$1.03M Sell
14,383
-1,268
-8% -$96.3K 0.18% 97
2017
Q3 		$1.27M Sell
15,651
-311
-2% -$23.8K 0.24% 76
2017
Q2 		$1.13M Buy
15,962
+3,755
+31% +$250K 0.24% 90
2017
Q1 		$829K Sell
12,207
-7,008
-36% -$493K 0.19% 97
2016
Q4 		$1.38M Sell
19,215
-38,100
-66% -$2.83M 0.27% 71
2016
Q3 		$4.53M Buy
57,315
+39,670
+225% +$3.22M 0.68% 42
2016
Q2 		$1.47M Buy
17,645
+375
+2% +$33.3K 0.24% 64
2016
Q1 		$1.59M Buy
17,270
+6,405
+59% +$578K 0.21% 67
2015
Q4 		$1.1M Buy
10,865
+1,369
+14% +$142K 0.15% 79
2015
Q3 		$932K Sell
9,496
-194,978
-95% -$21.7M 0.12% 93
2015
Q2 		$23.9M Buy
204,474
+192,379
+1,591% +$21M 2.57% 5
2015
Q1 		$1.19M Buy
12,095
+2,253
+23% +$229K 0.13% 89
2014
Q4 		$928K Buy
+9,842
New +$1.02M 0.13% 98

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Exane Derivatives's GILD Position: Q2 2022 in Review

Exane Derivatives reduced its Gilead Sciences (GILD) stake by 26% in Q2 2022, selling an estimated $300K and leaving 13,537 shares worth $837K. The position accounts for 0.48% of the portfolio, ranked #51.

Exane Derivatives first reported a position in GILD in Q4 2014 and has held it in 28 quarters since. The position peaked at $23.9M in Q2 2015. 1,604 funds tracked by Wall St. Rank hold GILD as of Q2 2022.

  • Exane Derivatives held 13,537 shares of Gilead Sciences worth $837K as of Q2 2022.
  • Exane Derivatives sold 4,847 Gilead Sciences shares in Q2 2022, an estimated $300K.
  • Gilead Sciences made up 0.48% of Exane Derivatives's portfolio in Q2 2022, its #51 holding.
  • Exane Derivatives first reported a position in Gilead Sciences in Q4 2014 and has held it in 28 quarters since.
  • Exane Derivatives's Gilead Sciences position peaked at $23.9M in Q2 2015.
  • 1,604 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.